US patent to be granted

US patent to be granted

31 July 2017

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces a further step in the expansion of its chemical modification patent estate.

Silence announces that the US Patent and Trade Mark Office has issued a notice of allowance for US patent application 15/589971.

Silence has made the relevant payment of grant fees and normal practice is that the granted patent will now be issued by the US Patent and Trade Mark Office. The allowed claims of US patent application 15/589971 provide Silence with further protection for its innovative chemical modification technology in the US. Silence believes these allowed claims are relevant to third party medicines in ongoing clinical trials.

Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented: 

"In allowing this additional patent application for grant, the US Patent and Trade Mark Office has continued to uphold the validity of our expanding US patent estate. We continue to believe that several third party late‐stage clinical RNAi candidates require licences under our patent portfolio."

Enquiries:

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.